Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Clinical Psychopharmacology|June 3, 2016
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover StudyKerri A Schoedel, Hong Sun, Edward M Sellers, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseaseDaniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
The New England Journal of Medicine|December 30, 2025
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
International Journal of Molecular Sciences|July 26, 2020
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II PatientsAkhil Bhalla, Ritesh Ravi, Meng Fang, et al.
Science Translational Medicine|November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patientsMatthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseDanna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, et al.
Clinical and Translational Science|June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patientsMaurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodentsZhi-Qiang Yang, Kelly-Ann S Schlegel, Youheng Shu, et al.
The Journal of Experimental Medicine|February 28, 2022
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzymeAnnie Arguello, Cathal S Mahon, Meredith E K Calvert, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 24, 2024
A framework for translating tauopathy therapeutics: Drug discovery to clinical trialsHoward H Feldman, Jeffrey L Cummings, Adam L Boxer, et al.
Pageof 9